Fructose stimulated de novo lipogenesis is promoted by inflammation.

Jelena Todoric; Giuseppe Di Caro; Saskia Reibe; Darren C Henstridge; Courtney R Green; Alison Vrbanac; Fatih Ceteci; Claire Conche; Reginald McNulty; Shabnam Shalapour; Koji Taniguchi; Peter J Meikle; Jeramie D Watrous; Rafael Moranchel; Mahan Najhawan; Mohit Jain; Xiao Liu; Tatiana Kisseleva; Maria T Diaz-Meco; Jorge Moscat; Rob Knight; Florian R Greten; Lester F Lau; Christian M Metallo; Mark A Febbraio; Michael Karin
Abstract
Benign hepatosteatosis, affected by lipid uptake, de novo lipogenesis and fatty acid (FA) oxidation, progresses to non-alcoholic steatohepatitis (NASH) on stress and inflammation. A key macronutrient proposed to increase hepatosteatosis and NASH risk is fructose. Excessive intake of fructose causes intestinal-barrier deterioration and endotoxaemia. However, how fructose triggers these alterations and their roles in hepatosteatosis and NASH pathogenesis remain unknown. Here we show, using mice, that microbiota-derived Toll-like receptor (TLR) agonists promote hepatosteatosis without affecting fructose-1-phosphate (F1P) and cytosolic acetyl-CoA. Activation of mucosal-regenerative gp130 signalling, administration of the YAP-induced matricellular protein CCN1 or expression of the antimicrobial peptide Reg3b (beta) peptide counteract fructose-induced barrier deterioration, which depends on endoplasmic-reticulum stress and subsequent endotoxaemia. Endotoxin engages TLR4 to trigger TNF production by liver macrophages, thereby inducing lipogenic enzymes that convert F1P and acetyl-CoA to FA in both mouse and human hepatocytes.
Journal NATURE METABOLISM
ISSN 2522-5812
Published 01 Oct 2020
Volume 2
Issue 10
Pages 1034-1045
DOI 10.1038/s42255-020-0261-2
Type Journal Article | Research Support, N.I.H., Extramural | Research Support, Non-U.S. Gov't
Sponsorship
Publication Files